World Health Organization Issues Warning Over Acute Shortage of Obesity Injections
Under 10% of people who could benefit from GLP-1 drugs such as Wegovy are able to get them, warns the WHO as it issues its inaugural guidance on the medications.
Given in excess of 1,000,000,000 people worldwide now living with obesity, it is urging more widespread and fairer access to this class of drugs.
According to estimates, over two billion will be living with obesity by 2030 if no action is taken.
"Our new guidelines affirms that excess weight is a lifelong illness that can be managed with comprehensive and ongoing support," stated the agency's head Tedros Adhanom Ghebreyesus.
High costs, limited production capacity, and logistical bottlenecks are significant barriers to widespread availability to the jabs that can aid individuals in losing substantial body mass, says the organization.
Weight-Loss Drug Shortage
Even under the present most favorable outlook, the manufacturing of GLP-1 therapies might only reach around 100 million people – fewer than 10% of those who need them, per the health organization.
The guideline encourages countries and companies to widen access, through strategies such as licensing agreements.
Exclusive production rights on a key compound – the primary component of a leading brand – is scheduled to end in a number of nations in 2026.
The Way Obesity Drugs Work
These medications imitate a natural hormone to slow digestion, curb appetite and boost satiety so users eat less.
Individuals typically start to lose weight after several weeks of starting on the weekly injections.
Evidence indicates users may see weight return within a year of stopping the treatment, because their typical appetite come back.
To be carrying excess weight increases your risk for contracting health problems, such as type 2 diabetes, cardiovascular issues, stroke, and some malignancies.
Obesity concerns individuals in every country and was linked to over three and a half million deaths worldwide in 2024, per the health agency.
